Formulation characterization and in-vitro evaluation of class 1c antiarrhythmic agent: propafenone into transdermal patches

In the present research work PROPAFENONE an anti-arrhythmia agent was selected for the formulation and preparation of transdermal patches as a model drug, using HPMC-15 cps and Methocel K100 as release controlling agents from patches along with sodium alginate are used. Transdermal patches were prepared using HPMC-15cps from trials T-1 to t-5, in which concentrations of HPMC-15 cps used in increasing concentrations. Similarly same in case of trials T6 to T10 was used with Methocel K 100. In-house films were taken for in-vitro evaluation tests and found to be 109 mg to 365 mg. whereas folding endurance test was found to be 56 times for TRIAL-1 and 126 times for TRIAL-10. In case of moisture content test TRIAL -10 showed less percent of moisture with 1.14 and TRIAL-4 Showed 3.54. For water uptake studies patches of TRAIL-10 absorbed 0.98 percent and TRIAL -2 of 1.63 percent. When comes to tensile strength of in-house prepared patches lease of TRIAL-6 with 63 and maximum of TRIAL-10 with 106. Release kinetics was also determined for optimized trial T10 and the drug release was found to be in following order, Zero order-0.995>Koresmeyer Peppas plot-0.972>First order>0.932>Higuchis plot-0.923. Based on the above R2 values it has been concluded that the release of PROPAFENONE was following Zero order rate kinetics with R2 value 0.995.